← SynDRA
ROSIGLITAZONE
SynDRA canonical compound SYN0001042 — structure-anchored drug synonym record
| Clinical phase | Withdrawn |
|---|
| Approval status | Approved · OTC |
|---|
| Primary target(s) | PPARG |
|---|
| Mechanism of action | PPAR receptor agonist |
|---|
| Indication | diabetes mellitus |
|---|
| Disease area | Insulin sensitizer |
|---|
All known targets
- PPARG
- TRPC5
- FFAR1
- TRPM3
- Maob
- TBXAS1
- SLC10A1
- RXRA
- RARG
- Pparg
- Ppara
- PPARD
Mechanisms of action (all sources)
- Insulin sensitizer
- PPAR receptor agonist
- PPARG AGONIST
- Peroxisome proliferator-activated receptor gamma agonist
- FFAR1 FULL AGONIST
- PPARG FULL AGONIST
- TRPC5 ACTIVATOR
- TRPM3 MODULATOR
- insulin sensitizer, ppar receptor agonist
Drug classes
- Peroxisome Proliferator-activated Receptor Activity
- Peroxisome Proliferator-activated Receptor gamma Agonists
- Hypoglycemic Agents
- Peroxisome Proliferator Receptor gamma Agonist
- Thiazolidinedione
ATC classes
- A10B · BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Cross-references
Synonyms
- rosiglitazone maleate
- rosiglizole
- rosiglitazone hydrochloride
- rosiglitazone HCl
- Rosiglitazona
- Avandamet
- Avandaryl
- Gaudil
- Rezult
- Rosiglizole
- Rosvel
- BRL-49653
- NSC-758698
- TDZ-01
- Avandia
- Nyracta
- Venvia
- Rosiglitazone XR
- Rosiglitazone Maleate [USAN]
- Rosiglitazone maleate
- BRL-49653C
- Avandia (TN)
- Avandiaadministration for 6-12 weeks
- BRL 49653-C
- SB-206846
- SB-210232
- Rosiglitazone maleate (JAN/USAN)
- (+-)-5-(p-(2-(Methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione maleate (1:1)
- (+-)-5-[[4-2-(methyl]-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,(Z)-2-butenedioate (1:1)
- 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (2Z)-2-butenedioate (1:1)
- 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1)
- 2,4-Thiazolidinedione,5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-,(2Z)-2-butenedioate
- 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
- 5-{[4-({2-[methyl(pyridin-2-yl)amino]ethyl}oxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione (2Z)-but-2-enedioate
- Brl 49653
- NSC 758698
- rosiglitazone (iarc)
- TDZ 01
Reported adverse events
- Lactic acid
- Lactic acidosis
- Arthralgia
- Back pain
- Fatigue
- Headache
- Hypertension
- Injury
- Nasopharyngitis
- Sinusitis
- Stevens-Johnson syndrome
- Upper respiratory tract infection
Look up ROSIGLITAZONE in the interactive SynDRA portal →